BGLC RSI Chart
Last 30 days
-7.9%
Last 90 days
-43.7%
Trailing 12 Months
7.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 9.8M | 0 | 0 | 0 |
2023 | 10.3M | 10.4M | 10.3M | 9.8M |
2022 | 12.9M | 12.3M | 11.3M | 10.9M |
2021 | 11.8M | 13.8M | 14.2M | 13.4M |
2020 | 0 | 0 | 0 | 11.4M |
2019 | 0 | 0 | 0 | 0 |
2018 | 0 | 0 | 0 | 212.3K |
Which funds bought or sold BGLC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -18,106 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -7,907 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -3,090 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | 3,954 | 16,718 | -% |
May 13, 2024 | HRT FINANCIAL LP | new | - | 15,000 | 15,000 | -% |
May 13, 2024 | UBS Group AG | new | - | 5,943 | 5,943 | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Feb 26, 2024 | Virtu Financial LLC | reduced | -56.19 | -36,000 | 14,000 | -% |
Unveiling Bionexus Gene Lab Corp.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bionexus Gene Lab Corp.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
APD | 58.5B | 12.2B | 23.67 | 4.81 | ||||
DOW | 41.7B | 43.5B | 32.86 | 0.96 | ||||
CE | 17.2B | 10.7B | 8.64 | 1.61 | ||||
AVTR | 17.0B | 6.9B | 65.29 | 2.47 | ||||
ALB | 15.4B | 8.4B | 45.68 | 1.84 | ||||
EMN | 11.8B | 9.1B | 12.77 | 1.3 | ||||
MID-CAP | ||||||||
CBT | 5.7B | 3.9B | 12.68 | 1.45 | ||||
BCPC | 5.1B | 929.6M | 44 | 5.44 | ||||
AVNT | 4.2B | 3.1B | 40.01 | 1.34 | ||||
ARCH | 2.9B | 3.0B | 9.11 | 0.99 | ||||
SMALL-CAP | ||||||||
CCF | 1.2B | 404.0M | 36.59 | 3 | ||||
ASIX | 667.0M | 1.5B | 293.44 | 0.45 | ||||
CMT | 172.0M | 336.4M | 9.44 | 0.51 | ||||
AREC | 103.7M | 16.7M | -8.76 | 6.19 | ||||
AMRS | 3.7M | - | -0.01 | 0.01 |
Bionexus Gene Lab Corp. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 4.8% | 2,381,851 | 2,273,067 | 2,553,686 | 2,566,848 | 2,377,205 | 2,839,575 | 2,575,086 | 2,485,101 | 3,028,945 | 3,245,271 | 3,575,966 | 3,092,171 | 3,449,159 | 4,125,886 | 3,091,012 | 1,103,516 | 3,070,026 | 1,547,100 | 24,173 | 21,645 | 28,088 |
Cost Of Revenue | 0.5% | 2,016,820 | 2,006,512 | 2,199,354 | 2,227,134 | 2,008,308 | 2,500,349 | 2,275,587 | 2,221,130 | 2,672,612 | 2,752,900 | 2,866,772 | 2,624,564 | 2,866,594 | 3,742,882 | 2,568,790 | 944,226 | 2,414,719 | 37,548 | 16,499 | 17,020 | -18,822 |
Gross Profit | 36.9% | 365,031 | 266,555 | 354,332 | 339,714 | 368,897 | 339,226 | 299,499 | 263,971 | 356,333 | 492,371 | 709,194 | 467,607 | 582,565 | 383,004 | 522,222 | 159,290 | 655,307 | 34,323 | 7,674 | 4,625 | 9,266 |
S&GA Expenses | 100.0% | - | -16,955 | 3,082,128 | 807,077 | 536,872 | 487,852 | 418,824 | 454,783 | 368,036 | 198,069 | 383,401 | 378,046 | 302,851 | 493,528 | 294,005 | 216,993 | 328,418 | 212,321 | 63,097 | 81,224 | -76,489 |
EBITDA Margin | -1.1% | -0.26 | -0.26 | -0.28 | -0.04 | -0.03 | -0.02 | 0.10 | 0.09 | 0.09 | 0.09 | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 636.4% | 4,661 | -869 | 4,259 | 3,042 | 2,445 | 77.00 | 2,072 | 2,319 | 3,326 | 3,986 | 2,150 | 3,479 | 3,358 | 4,551 | 2,356 | 7,432 | -3,026 | -2,752 | -804 | -570 | -921 |
Income Taxes | 79.5% | -20,068 | -97,944 | 76,418 | -46,625 | 15,990 | -75,102 | 10,114 | -1,621 | 14,299 | -474,732 | 75,169 | 108,280 | - | 170,141 | -492 | 487 | 860 | -2,087 | 28,110 | 1,179 | -1,264 |
Earnings Before Taxes | -133.0% | -83,689 | 253,571 | -2,532,771 | -275,241 | -53,076 | -127,451 | -67,287 | -140,283 | 31,365 | - | 370,491 | 136,542 | - | - | - | - | - | - | - | - | - |
EBT Margin | -1.1% | -0.27 | -0.27 | -0.29 | -0.05 | -0.04 | -0.03 | 0.09 | 0.08 | 0.08 | 0.08 | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -133.6% | -103,757 | 308,463 | -2,609,189 | -259,251 | -69,066 | -156,969 | -77,401 | -138,662 | 17,066 | 89,243 | 295,322 | 28,262 | 338,744 | -174,163 | 234,458 | -35,841 | 1,069,644 | -92,576 | -22,028 | -70,398 | -61,467 |
Net Income Margin | -1.3% | -0.27 | -0.27 | -0.30 | -0.05 | -0.04 | -0.03 | -0.01 | 0.02 | 0.03 | 0.06 | 0.03 | 0.03 | 0.03 | 0.10 | - | - | - | - | - | - | - |
Free Cashflow | 200.5% | 114,001 | -113,466 | -1,033,348 | -36,400 | -118,399 | 513,883 | 305,231 | -197,262 | -70,030 | 481,728 | 315,459 | -905,809 | 114,621 | 511,166 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.1% | 11,161 | 11,400 | 11,466 | 7,899 | 8,187 | 8,740 | 7,798 | 8,369 | 9,175 | 9,574 | 9,765 | 9,448 | 9,899 | 10,115 | 1,013 | 1,060 | 1,127 | 1,231 | 1,344 | 1,513 | 1,607 |
Current Assets | -1.8% | 7,905 | 8,047 | 8,270 | 5,227 | 5,459 | 6,022 | 5,409 | 5,766 | 6,601 | 7,150 | 7,402 | 7,099 | 7,563 | 7,985 | 720 | 763 | 808 | 883 | 1,016 | 1,171 | 1,250 |
Cash Equivalents | -1.6% | 5,832 | 5,929 | 6,147 | 1,759 | 1,973 | 2,119 | 1,462 | 1,340 | 1,844 | 2,124 | 1,700 | 1,483 | 2,475 | 2,788 | 2,190 | 1,287 | 1,397 | 859 | 977 | 1,140 | 597 |
Inventory | -5.3% | 1,077 | 1,138 | 1,108 | 1,166 | 900 | 978 | 1,096 | 1,512 | 1,649 | 1,522 | 1,488 | 1,703 | 1,469 | 1,176 | 19.00 | 21.00 | 7.00 | 8.00 | 12.00 | 6.00 | 10.00 |
Net PPE | -2.6% | 1,472 | 1,512 | 1,497 | 1,397 | 1,482 | 1,512 | 1,440 | 1,533 | 1,628 | 1,634 | 1,647 | 1,684 | 1,708 | 1,786 | 277 | 279 | 288 | 313 | 316 | 330 | 345 |
Liabilities | 4.3% | 1,817 | 1,742 | 1,778 | 1,935 | 1,630 | 2,075 | 1,375 | 1,547 | 2,047 | 2,395 | 2,713 | 2,635 | 3,106 | 3,453 | 1,772 | 91.00 | 94.00 | 109 | 81.00 | 123 | 130 |
Current Liabilities | 5.2% | 1,717 | 1,631 | 1,644 | 1,876 | 1,563 | 2,004 | 1,335 | 1,503 | 1,985 | 2,329 | 2,665 | 2,576 | 3,035 | 3,374 | 38.00 | 46.00 | 47.00 | 52.00 | 27.00 | 64.00 | 66.00 |
Shareholder's Equity | -3.2% | 9,344 | 9,658 | 9,688 | 5,964 | 6,557 | 6,665 | 6,424 | 6,822 | 7,128 | 7,180 | 7,052 | 6,813 | 6,792 | 6,662 | 6,682 | 6,200 | 6,192 | 1,122 | 1,264 | 1,390 | 1,478 |
Retained Earnings | -5.6% | -1,948 | -1,844 | -1,781 | 828 | 1,087 | 1,156 | 1,313 | 1,391 | 1,529 | 1,512 | 1,423 | 1,128 | 1,100 | 761 | -507 | -447 | -381 | -333 | -240 | -218 | - |
Additional Paid-In Capital | 0% | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 | -5,011 |
Shares Outstanding | 0% | 17,668 | 17,668 | 17,793 | 173,718 | 173,718 | 14,477 | 173,718 | 171,218 | 171,218 | 171,218 | 171,218 | 171,218 | 171,218 | 171,218 | - | - | - | - | - | - | - |
Float | - | - | - | - | 66,500 | - | 48,487 | - | - | - | - | - | 41,737 | - | - | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 86.8% | -34.44 | -261 | -899 | -22.04 | -118 | 477 | 309 | -195 | -37.84 | 483 | 316 | -905 | 115 | 932 | 755 | -157 | -977 | -58.36 | -57.41 | -52.93 | -48.56 |
Cashflow From Investing | 275.2% | 24.00 | -13.75 | -360 | -3.06 | -5.06 | -49.90 | 18.00 | -221 | -197 | -76.29 | -58.58 | -59.88 | -295 | -416 | 4.00 | 20.00 | 1,712 | -7.14 | 4.00 | 5.00 | -14.63 |
Cashflow From Financing | 117.9% | 24.00 | 11.00 | 5,747 | -2.43 | -1.78 | -2.27 | -1.74 | 112 | - | -4.96 | -6.08 | -8.63 | -8.55 | 2.00 | 2.00 | -2.99 | -6.40 | -73.47 | -98.63 | -5.09 | -3.61 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||
REVENUE | $ 2,381,851 | $ 2,377,205 |
COST OF REVENUE | (2,016,820) | (2,008,308) |
GROSS PROFIT | 365,031 | 368,897 |
OTHER INCOME | 201,847 | 117,344 |
OPERATING EXPENSES | ||
General and administrative | (645,906) | (536,872) |
LOSS FROM OPERATIONS | (79,028) | (50,631) |
FINANCE COSTS | (4,661) | (2,445) |
LOSS BEFORE TAX | (83,689) | (53,076) |
Tax expense | (20,068) | (15,990) |
NET LOSS | (103,757) | (69,066) |
Other comprehensive income: | ||
Foreign currency translation loss | (209,908) | (39,039) |
COMPREHENSIVE LOSS | $ (313,665) | $ (108,105) |
Earnings per share - Basic and diluted | $ (0.018) | $ (0.007) |
Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 10. | 17,667,663 | 14,476,513 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash and bank balances | $ 2,489,215 | $ 2,623,965 |
Fixed deposits placed with financial institutions | 3,342,966 | 3,305,371 |
Trade receivables | 839,558 | 799,674 |
Other receivables, deposits and prepayments | 106,304 | 122,432 |
Tax Recoverable | 50,441 | 57,588 |
Inventories | 1,076,953 | 1,137,770 |
Total current assets | 7,905,437 | 8,046,800 |
NON-CURRENT ASSETS | ||
Operating lease right of use assets | 128,176 | 141,544 |
Property, plant and equipment, net | 1,471,638 | 1,511,618 |
Other investments | 1,656,232 | 1,699,831 |
Total non-current assets | 3,256,046 | 3,352,993 |
TOTAL ASSETS | 11,161,483 | 11,399,793 |
CURRENT LIABILITIES | ||
Trade payables | 1,429,162 | 1,402,180 |
Other payables and accrued liabilities | 214,735 | 180,912 |
Current portion of operating lease liabilities | 32,508 | 34,632 |
Amount owing to directors | 40,129 | 13,199 |
Total current liabilities | 1,716,534 | 1,630,923 |
NON-CURRENT LIABILITIES | ||
Non-current portion of operating lease liabilities | 88,846 | 98,763 |
Deferred tax liabilities | 11,916 | 12,255 |
Total non-current liabilities | 100,762 | 111,018 |
TOTAL LIABILITIES | 1,817,296 | 1,741,941 |
STOCKHOLDERS' EQUITY | ||
As at March 31, 2024, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2023, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*. | 17,191,315 | 17,191,315 |
Additional paid in capital | (5,011,891) | (5,011,891) |
Accumulated deficit | (1,948,035) | (1,844,278) |
Other comprehensive losses | (887,202) | (677,294) |
TOTAL STOCKHOLDERS' EQUITY | 9,344,187 | 9,657,852 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 11,161,483 | $ 11,399,793 |